The word longevity now sits beside almost anything for sale — infusions, plunges, panels, packages, peptides. Some of it is defensible. Most of it is not. The asymmetry between what is promised and what the evidence supports is wide enough that an intelligent reader can be forgiven for not knowing where to begin.
The shape of the market
Narrower analyst definitions place the global longevity category at roughly USD 25 to 32 billion in 2025–26, with supplements taking around forty per cent of revenue and wearables, diagnostics and concierge clinics filling out most of the rest. Broader wellness framings reach the trillions but conflate categories that have little to do with one another. Venture capital flows tell a more concentrated story: a rebound to roughly USD 8.5 billion across 331 deals in 2024, dominated by a small number of cellular-reprogramming and epigenetic-editing companies — Altos, Retro, BioAge, NewLimit — none of which has yet produced human clinical readouts. The marquee compounds and the marquee companies are real. They are also early.
What the clinics actually sell
Strip away the user experience and most longevity programmes deliver a structured cardiometabolic risk assessment, an extended panel with ApoB and sometimes Lp(a), DEXA and VO₂max, a CT coronary calcium score where indicated, wearable data, and integrated behaviour-change support across a year. The premium pays for time, continuity and integration — for which there is a small but real mortality signal of its own. The underlying medicine is preventive, not novel. Australian providers including Everlab, HealthScreen, Vively, Human Longevity Project Australia, BOOST Health Sciences and Australian Longevity Group occupy this competitive set. The closure of Forward Health in the United States in late 2024, after raising more than half a billion dollars, is a salient reminder that consumer longevity has unit-economics problems even when the medicine is sound.
What the evidence actually supports
If a single drug produced the effect sizes that exercise, Mediterranean-pattern eating and seven hours of sleep produce, it would be the best-selling pharmaceutical in history. Mandsager's 2018 cohort of more than 122,000 adults found that higher cardiorespiratory fitness was associated with lower all-cause mortality without an observed upper limit of benefit. Resistance training and grip strength add benefit independent of aerobic work. Sleep risk is U-shaped, lowest near seven hours. Adherence, not novelty, is the bottleneck. The defensible diagnostic core is similarly unglamorous: ApoB and a once-in-a-lifetime Lp(a) measurement, CT coronary calcium scoring in selected adults, DEXA where indicated, considered use of CT coronary angiography, stress imaging, prostate MRI and a non-invasive liver scan when a question warrants them. Whole-body MRI in low-risk healthy adults remains, on balance, a way to manufacture incidental findings.
Where the hype lives
The thinner end of the evidence base is where most of the marketing concentrates. Off-label rapamycin sits on persuasive mouse data and a single forty-eight-week human safety trial of an underdosed compounded formulation; the definitive RCT in healthy adults has not been done. NAD precursors elevate NAD and move intermediate biomarkers; no hard-endpoint human evidence exists. Senolytic stacks remain Phase 1 and 2 with mixed signals. Plasma exchange, exosome and stem-cell offerings have neither approval nor convincing human geroprotective data. Biological-age reversal packages rest, at the human level, principally on a nine-person open-label trial from 2019. None of this is fraudulent on its face. It is simply earlier than the marketing implies.
The Australian regulatory perimeter
The direction of Australian regulation through 2024 and 2025 has been unambiguously restrictive. Compounded GLP-1 receptor agonists were removed from the pharmacist exemption on 1 October 2024. AHPRA's non-surgical cosmetic guidelines, effective 2 September 2025, prohibit asynchronous prescribing of cosmetic injectables, ban influencer testimonials, and tighten the rules on advertising to under-eighteens — a model likely to extend by analogy to hormone-optimisation and longevity marketing. NMN was added to the permissible-ingredients list on 10 December 2025, but with a 500 mg daily cap, restriction to adults, and a two-year sponsor exclusivity period; listing is not an endorsement of efficacy. The TGA has issued infringement notices to IV-infusion providers (Mode Medical, AUD 159,840), to NMN advertisers making disease claims (Switch Nutrition, AUD 79,200), and has secured a ten-million-dollar Federal Court penalty against Peptide Clinics. Peptides remain accessible only via the Special Access Scheme or as an Authorised Prescriber, which is a clinical pathway rather than a marketing one. Stem-cell and exosome therapies fall under the Biologicals Framework, and supply of an unapproved biological is a criminal offence.
Genetics, briefly
The centenarian-genetics narrative is thinner than the popular telling suggests. Only two genes — APOE and FOXO3 — have survived repeated study as longevity-associated genes across populations. The more practically useful story sits with rare genetic variants that switch off PCSK9 and ANGPTL3 — variants that lower lifetime cardiovascular risk in the few people born with them, and are now being copied as drugs for everyone else. Whole-genome sequencing in healthy adults without a specific question sits closer to the over-investigation end of the spectrum than the personalised-medicine end; targeted pharmacogenomics — testing genes that change how a person handles a specific drug — has begun to move into Medicare-supported practice.
The honest reframe
Most of what private longevity care offers in Australia is high-evidence preventive medicine in concierge packaging. The mortality dividend from doing the basics well — training, eating, sleeping, screening, treating cardiometabolic risk early — dwarfs anything currently sold as longevity therapy. Honest practice says so plainly, spends its effort there, and adds investigation only when investigation will change a decision. Care shaped around the person, rather than around whatever is currently easy to sell.
§ For professionals — mechanisms & evidence+
Market structure and capital flows
Mordor Intelligence places the broader longevity market at USD 31.6 B in 2026, projected to USD 46.9 B by 2031 (8.18% CAGR), with North America at 41.2% revenue share and no firm above 5%. InsightAce's narrower "longevity and anti-senescence therapy" segment sits at USD 27.1 B (2023) with ~6.8% CAGR. Supplements represent ~42% of revenue. Longevity.Technology's 2024 annual report records USD 8.49 B across 331 deals — a rebound from the USD 3.8 B 2023 trough — concentrated in Altos Labs (USD 3 B), Retro Biosciences (Series A in progress, chasing a USD 5 B valuation per STAT News, 3 Dec 2025), BioAge (USD 238.3 M IPO, Oct 2024), and NewLimit (USD 130 M Series B, May 2025; subsequently USD 45 M from Eli Lilly/Section 32). 83% of capital is US-based.
Pharmacology — what has hard-endpoint data
The cardiometabolic class carries the only hard-endpoint mortality data in indicated populations: statins, PCSK9 inhibitors, SGLT2 inhibitors, and now GLP-1 receptor agonists. SELECT (Lincoff, NEJM 2023; n=17,604) showed a 20% MACE reduction in non-diabetic adults with overweight/obesity and established CVD (NNT ≈ 67 over ~40 months). Repositioning GLP-1s as "longevity drugs" is defensible in cardiometabolic-risk groups but not as healthspan extension in metabolically healthy adults. The TRAVERSE trial (Lincoff, NEJM 2023; n=5,246) found testosterone gel non-inferior to placebo for MACE in hypogonadal men with high CV risk but flagged excess atrial fibrillation, PE and AKI — providing no basis for TRT in eugonadal men.
Metformin's exercise interaction
The TAME composite (CVD, cognitive decline, cancer, mortality) is still recruiting. Two findings complicate enthusiasm: Konopka 2019 (Aging Cell) showed metformin blunts the aerobic-exercise-induced increase in whole-body insulin sensitivity and mitochondrial respiration adaptations, and Walton 2019 (MASTERS, Aging Cell) found placebo gained more lean and thigh muscle mass than metformin during fourteen weeks of resistance training in adults ≥65. Putative geroprotection may trade off against fitness adaptation.
Senolytics and NAD precursors
Hickson 2019 (EBioMedicine) first demonstrated dasatinib + quercetin reduced senescent-cell burden in diabetic kidney disease (small, open-label). Subsequent trials in IPF, AD and frailty have produced mixed Phase 1/2 signals with no hard endpoints; Unity Biotechnology pivoted away from systemic senolytics. NR (Martens 2018; Dollerup 2018; Conze 2019) and NMN (Yi 2023; Yamaguchi 2024; Igarashi 2022) elevate NAD and move modest functional surrogates. None has reported mortality or morbidity data.
Peptides and the Australian access pathway
BPC-157, TB-500, ipamorelin, CJC-1295 and sermorelin remain largely preclinical and are on the WADA prohibited list (S0 unapproved). They are not on the ARTG; legal access requires SAS Cat A/B/C or Authorised Prescriber status — neither of which constitutes a marketing pathway. The TGA secured an AUD 10 M Federal Court penalty against Peptide Clinics for advertising breaches, executed a search warrant on a South Yarra pharmacy in March 2024, and has issued infringement notices to individuals importing unapproved peptides. The recent US softening of posture has no Australian counterpart.
Plasma exchange, stem cells, exosomes, NAD IVs
Young-plasma transfusion (Ambrosia) ceased after the FDA's 2019 safety communication. Stem-cell and exosome therapies fall under the TGA Biologicals Framework; supplying an unapproved biological for therapeutic use is a criminal offence under TG Act s 32BD, and autologous HCT products cannot be advertised. Mode Medical (Drip IV Australia) and its executive officer were issued twenty infringement notices totalling AUD 159,840 for IV-infusion advertising claims spanning cancer, COVID-19 fatigue, Alzheimer's, MS and Graves' disease, plus promotion of prescription-only glutathione.
Diagnostics — what is defensible
Reliable: ApoB, Lp(a), HbA1c, hsCRP, blood pressure, VO₂max, grip strength, DEXA, CAC, eGFR/UACR, liver elastography. Promising at population level but not yet actionable for the individual: DunedinPACE (Belsky 2022, eLife; validated across 65+ cohorts in 17+ countries), proteomic clocks (GlycanAge, Nightingale NMR), inflammaging panels. Multi-cancer early detection (Galleri/GRAIL) is advancing — PATHFINDER 2 (Jun 2025) reported 92% Cancer Signal Origin accuracy with PPV 61.6% and specificity 99.6%, and a seven-fold uplift in cancers detected when added to USPSTF screening — but the NHS-Galleri pre-specified late-stage primary endpoint was not met across all analyses in the Feb 2026 topline. A meaningful minority of positives remain false positives with cascade costs.
The biotech pipeline
Altos Labs (cellular reprogramming, Hal Barron CEO, no human clinical readouts), Retro Biosciences (Sam Altman–backed, first-in-human trial slated in Australia), BioAge (BGE-102 NLRP3 inhibitor in Phase 1; azelaprag discontinued Dec 2024 on STRIDES futility), NewLimit (epigenetic reprogramming, liver-focused), Insilico Medicine (rentosertib, the first peer-reviewed Phase 2a clinical readout for a generative-AI-designed drug — Nature Medicine, 3 June 2025: FVC +98.4 mL versus −20.3 mL placebo in IPF). Loyal's LOY-002 in dogs is the nearest sentinel: FDA CVM has accepted Reasonable Expectation of Effectiveness (Feb 2025) and Target Animal Safety (Jan 2026); the STAY study (1,300 dogs) is fully enrolled. Disease-specific approvals 2026–2030 are plausible. A true geroprotector pathway awaits FDA or EMA acceptance of an ageing composite endpoint or surrogate — neither yet endorsed.
"Biological age reversal" — the TRIIM caveat
TRIIM (Fahy 2019, Aging Cell) reported a ~2.5-year reduction in mean epigenetic age across four clocks in nine men aged 51–65 after one year of GH + DHEA + metformin. Open-label, n=9, no placebo control, one prostate-cancer case during the trial, raised IGF-1, intermediate biomarker only. TRIIM-X (NCT04375657) is ongoing; no peer-reviewed Phase 2 publication as of mid-2025. Bryan Johnson's Project Blueprint runs at approximately USD 2 M per year of personal spend and publicly discontinued rapamycin in late 2024 citing biomarker side-effects. Theatre value high; generalisable hard-endpoint evidence: nil.
Australian regulatory perimeter — recent enforcement
GLP-1 compounding ban: removed from pharmacist extemporaneous compounding exemption effective 1 October 2024 (TG Regulations 1990, Sch 5 item 6). AHPRA non-surgical cosmetic guidelines (effective 2 September 2025): in-person or video consultation required for each prescription of a cosmetic injectable; bulk/asynchronous prescribing prohibited; influencer testimonials banned; nurses require twelve months full-time practice. NMN listed 10 December 2025 (Permissible Ingredients Determination No. 4, 2025) with 500 mg/day cap, adults only, and two-year sponsor exclusivity to Longevity Life Sciences Pty Ltd. Compliance scale: TGA requested removal of more than 13,700 advertisements or online profiles in 2024–25. Advertising of prescription-only medicines to consumers (rapamycin, semaglutide, tirzepatide) remains prohibited under TG Act s 42DLB.
The honest middle ground
The mortality dividend from doing the basics well — cardiorespiratory fitness (Mandsager 2018, JAMA Network Open: inverse association without an observed upper limit), resistance and grip strength (Leong 2015, PURE), Mediterranean-pattern eating (PREDIMED, Estruch 2018, NEJM), seven hours of sleep (U-shape across cohorts >2M), smoking and alcohol minimisation, and early treatment of cardiometabolic risk — dwarfs anything currently sold under the longevity banner. Risk-refinement diagnostics (ApoB, Lp(a), CAC, DEXA) used judiciously rather than as packaging. Imaging only what a question warrants. Off-label rapamycin, NAD/NMN/NR products, senolytic stacks, peptides, NAD IVs, and biological-age reversal packages do not yet have controlled human evidence of healthspan extension in healthy adults.
How large is the global longevity market, really?+
Analyst estimates vary by an order of magnitude depending on what is counted. Narrower 'longevity and anti-senescence' definitions sit around USD 25–32 billion in 2025–26 (InsightAce, Mordor Intelligence), with supplements representing roughly forty per cent of revenue, followed by wearables, diagnostics, and concierge clinics. Broader 'wellness' framings reach the trillions but mean something quite different. Approved gerotherapeutics contribute essentially nothing to current revenue.
What do longevity clinics actually deliver, mechanically?+
A structured intake, an extended panel (typically ApoB, occasionally Lp(a), HbA1c, hsCRP, hormones), DEXA, VO₂max, ECG, CT coronary calcium in selected adults, wearable data, and integrated behaviour-change support over six to twelve months. The premium pays for time, continuity and integration — defensible, and consistent with the Pereira Gray 2018 BMJ Open finding that continuity of care is associated with lower mortality. The underlying medicine is preventive, not novel.
Where does the Australian regulator currently sit?+
Restrictive, and tightening. Compounded GLP-1 receptor agonists were removed from the pharmacist exemption on 1 October 2024. AHPRA's non-surgical cosmetic guidelines (effective 2 September 2025) prohibit asynchronous prescribing and influencer testimonials. NMN was listed as a permissible ingredient on 10 December 2025 under tight conditions (500 mg/day cap, adults only, two-year sponsor exclusivity). The TGA has issued infringement notices to IV-infusion and anti-ageing supplement advertisers and secured a ten-million-dollar Federal Court penalty against Peptide Clinics.
Is rapamycin a longevity drug?+
It extends lifespan in mice across the NIH Interventions Testing Program. The first reasonably-sized human trial (PEARL, 2025, n=114 completers) found no significant excess of moderate-to-severe adverse events versus placebo over forty-eight weeks of compounded weekly dosing, with some signals on body composition and quality-of-life subgroups — but the compounded formulation studied is roughly three and a half times less bioavailable than the commercial product, and a definitive RCT in healthy adults has not been done. Sirolimus is registered in Australia for transplant immunosuppression only; consumer-facing anti-ageing promotion contravenes the prescription-only advertising prohibition.
What about NMN and other NAD precursors?+
Human trials of NR and NMN consistently elevate NAD levels and produce modest cardiometabolic or anti-inflammatory signals on intermediate biomarkers. None has reported hard-endpoint data. NMN's Australian listing in December 2025 confirmed that the product can be entered on the ARTG under tight conditions — it does not constitute a TGA assessment of efficacy. Marketing claims for treatment of serious medical conditions remain prohibited; Switch Nutrition was issued infringement notices totalling AUD 79,200 in 2025 for advertising of this kind.
Are biological-age clocks ready for individual decision-making?+
Not yet, in isolation. DunedinPACE is currently the best-validated pace-of-ageing measure and the most responsive to intervention — the CALERIE trial slowed it by two to three per cent, an effect the authors framed as comparable in magnitude to smoking cessation. Clocks disagree with one another, and no trial has shown that acting on an epigenetic age number, as opposed to the underlying biology it summarises, reduces mortality. Used as one input among many, defensible; used as the headline number, misleading.
- Mordor Intelligence. Longevity and Anti-Senescence Therapy Market (Jan 2026).
- InsightAce Analytic. Global Longevity and Anti-Senescence Therapy Market, 2024.
- Longevity.Technology. Annual Investment Report 2024 — USD 8.49 B across 331 deals.
- Mandsager K et al. Association of Cardiorespiratory Fitness with Long-term Mortality. JAMA Network Open 2018;1(6):e183605.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM 2023;389:2221-2232.
- Lincoff AM et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE). NEJM 2023;389:107-117.
- López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell 2023;186(2):243-278.
- Zalzala S et al. PEARL — Rapamycin in healthy adults. Aging 2025; NCT04488601.
- Konopka AR et al. Metformin inhibits mitochondrial adaptations to aerobic exercise. Aging Cell 2019.
- Walton RG et al. Metformin blunts muscle hypertrophy in response to resistance training (MASTERS). Aging Cell 2019.
- Hickson LJ et al. Senolytics decrease senescent cells in humans. EBioMedicine 2019;47:446-456.
- Belsky DW et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife 2022;11:e73420.
- Waziry R et al. CALERIE — Effect of long-term caloric restriction on DNA methylation measures of biological aging. Nature Aging 2023.
- Fahy GM et al. Reversal of epigenetic aging and immunosenescent trends in humans (TRIIM). Aging Cell 2019.
- Pereira Gray DJ et al. Continuity of care with doctors — a matter of life and death? BMJ Open 2018;8:e021161.
- Insilico Medicine. Rentosertib (TNIK inhibitor) Phase 2a IPF readout. Nature Medicine, 3 June 2025.
- Therapeutic Goods Administration. Compounded GLP-1 RAs removed from pharmacist extemporaneous exemption, effective 1 October 2024.
- Therapeutic Goods Administration. Permissible Ingredients Determination No. 4, 2025 — NMN listed 10 December 2025.
- AHPRA. Guidelines for registered medical practitioners who perform non-surgical cosmetic procedures (effective 2 September 2025).
- Therapeutic Goods Administration. Infringement notices — Peptide Clinics, Mode Medical (Drip IV Australia), Switch Nutrition (2024–2025).